Methods for quantifying biospecimen sample integrity using oxidation. Embodiments include assessing ex vivo oxidation of a biospecimen sample by quantifying a difference in protein oxidation of the biospecimen sample in comparison to protein oxidation of a portion of the biospecimen sample intentionally incubated to cause oxidation to hit its maximum value. The difference in a level of oxidation in the biospecimen sample and the potion of the biospecimen sample is then inversely proportional to the degree of ex vivo oxidation.

The present disclosure relates to a marker for diagnosing neurodegenerative diseases, and a use thereof, and, more particularly, to: a marker composition for diagnosing neurodegenerative diseases; a composition for diagnosing neurodegenerative diseases, containing a preparation for measuring the glutathionylation level of a FUS protein; a kit for diagnosing neurodegenerative diseases, containing the composition; and an information providing method for diagnosing neurodegenerative diseases by using same. The inventors have discovered that a glutathionylated FUS protein functions as a marker for diagnosing neurodegenerative diseases, and thus a composition for diagnosing neurodegenerative diseases, according to the present disclosure, is expected to contribute to early diagnosis of patients with neurodegenerative diseases.

In addition, the present disclosure identifies GSTO1 or GstO2, which is a factor inducing the deglutathionylation of a FUS protein, so as to ascertain effects of inhibiting brain cytoplasmic aggregation and neurocytotoxicity by using same, and thus is expected to be effectively used for preventing, treating or alleviating neurodegenerative diseases.

Provided are methods of reducing and/or preventing interference by a drug comprising (i) an antibody Fc region and (ii) a moiety that binds to human CD47 in serological assays.

The free thiol group present in free cysteines in recombinant therapeutic antibodies are reactive to process components and generates product variants during early stages of biosimilar development. Free thiol group present on the structural motifs, especially in the complementary determining regions (CDR), support maximal antigen binding capability. Product variants associated with these free thiol groups are detrimental for safety and efficacy of these therapeutic antibodies. Methods to identify and characterize various thiol variants an antibody composition is provided and an anti-IL-17A IgG1 composition having these thiol variants are described.

Methods for quantifying biospecimen sample integrity using oxidation. Embodiments include assessing ex vivo oxidation of a biospecimen sample by quantifying a difference in protein oxidation of the biospecimen sample in comparison to protein oxidation of a portion of the biospecimen sample intentionally incubated to cause oxidation to hit its maximum value. The difference in a level of oxidation in the biospecimen sample and the portion of the biospecimen sample is then inversely proportional to the degree of ex vivo oxidation.

The present invention refers to inhibitors of microtubule polyglutamylation in mitosis for use as a medicament, preferably in the treatment of diseases benefiting from the inhibition of microtubule polyglutamylation in mitosis, most preferably in the treatment of cancer.